Consider an investment in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, whose stock has dropped over 55% this year due to competition from cheaper, unapproved drugs. A significant turnaround could be triggered by the company's aggressive legal strategy, which includes over 100 lawsuits filed against these competitors. If these legal actions succeed in removing "knockoff" products from the market, NVO could reclaim its market share and see its stock rebound. Adding to the bullish case, several U.S. lawmakers have recently been purchasing shares, suggesting they may anticipate a positive outcome. This is a high-risk turnaround play where investors should closely monitor the progress of Novo Nordisk's lawsuits.

Novo Nordisk AS (NVO)

• This is a Danish pharmaceutical company whose stock is down over 55% so far this year, despite making the popular weight loss drugs Ozempic and Wegovy.
• The stock is trading at a lower price than when its drugs first went viral a couple of years ago.
• Reason for Decline: The primary reason for the stock's poor performance is competition from companies making cheaper, compounded GLP-1 drugs, which has eroded Novo Nordisk's market share and growth expectations.
• Unusual Buying Activity: Several U.S. lawmakers, including Marjorie Taylor Greene, Lisa McClain, and Scott Franklin, have been "quietly loading up on shares" of NVO.
• Potential Catalysts for a Turnaround:
  • Legal Action: The company has filed over 100 lawsuits in U.S. federal courts against compounding pharmacies and telehealth companies that market "unapproved knockoff versions" of its drugs. A successful outcome could significantly reduce competition.
  • Lobbying Efforts: Novo Nordisk has dramatically increased its lobbying spending in the U.S. from "virtually zero in 2022 to spending millions over the past couple of years." The podcast suggests that stocks of companies that ramp up lobbying tend to outperform the market.
  • Corporate Strategy: The company appointed a new CEO in August to "revamp the company" and is pursuing a direct-to-consumer sales model for its GLP-1 drugs.

Takeaways

• Investment Thesis: The investment case for NVO is a turnaround story. The central idea is that the stock, currently trading near multi-year lows, could rebound significantly if the company succeeds in its lawsuits to remove cheaper, "knockoff" competitors from the market.
• "Smart Money" Signal: The buying activity from multiple U.S. lawmakers is highlighted as a significant bullish signal. The implication is that these insiders may anticipate that Novo Nordisk's legal and lobbying efforts will be successful.
• Key Factor to Monitor: Investors should pay close attention to the progress and outcomes of Novo Nordisk's lawsuits. Favorable rulings for the company would be a major positive catalyst for the stock.
• Risk: The podcast explicitly refers to this as potentially "trying to catch a falling knife." This implies that while the potential upside is significant, the risk is also high. The investment's success is heavily dependent on the company winning its legal battles.